Eli Lilly & Company, Shanghai, 200021, China.
Real World Solutions, IQVIA, Shanghai, 200126, China.
Future Oncol. 2022 May;18(15):1896-1905. doi: 10.2217/fon-2021-1336. Epub 2022 Mar 21.
To evaluate sintilimab compared with other PD-L1 inhibitors in combination with platinum-based doublet chemotherapy as the first-line treatment of non-squamous non-small-cell lung cancer. A frequentist meta-analysis was used to compare outcomes, including progression-free survival, overall survival, objective response rate, time to response and safety profile. The sintilimab combination arm had progression-free survival comparable to that of the pembrolizumab combination arm (hazard ratio [HR] = 1.00; 95% CI: 0.71, 1.41), the atezolizumab combination arm (HR: 0.81; 95% CI: 0.59, 1.10), the tislelizumab combination arm (HR: 0.75; 95% CI: 0.48, 1.16), the camrelizumab combination arm (HR: 0.80; 95% CI: 0.54, 1.20) and the nivolumab combination arm (HR: 0.72; 95% CI: 0.51, 1.02). Any grade or grade ≥3 adverse event was comparable between PD-L1 inhibitors. Sintilimab showed a comparable efficacy and safety profile when compared with other PD-L1 inhibitors combined with platinum-based doublet chemotherapy as the first-line treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer.
评估信迪利单抗联合铂类双药化疗与其他 PD-L1 抑制剂作为非鳞状非小细胞肺癌一线治疗的疗效。采用频率论方法进行荟萃分析比较了无进展生存期、总生存期、客观缓解率、缓解时间和安全性特征。信迪利单抗联合组与帕博利珠单抗联合组（风险比[HR] = 1.00；95%置信区间：0.71，1.41）、阿特珠单抗联合组（HR：0.81；95%置信区间：0.59，1.10）、替雷利珠单抗联合组（HR：0.75；95%置信区间：0.48，1.16）、卡瑞利珠单抗联合组（HR：0.80；95%置信区间：0.54，1.20）和纳武利尤单抗联合组（HR：0.72；95%置信区间：0.51，1.02）的无进展生存期相当。PD-L1 抑制剂的任何级别或≥3 级不良事件发生率相当。信迪利单抗联合铂类双药化疗作为局部晚期或转移性非鳞状非小细胞肺癌的一线治疗，与其他 PD-L1 抑制剂相比具有相当的疗效和安全性。
